Molecular Predictors of Cancer in Patients at High Risk of Lung Cancer

This observational study is looking for molecular changes that happen as lung cancer develops. Researchers are collecting samples like blood, urine, sputum (mucus from your lungs), and a small amount of lung tissue from people at high risk for lung cancer. They will use genetic tests, such as comparative genomic hybridization and gene expression microarray analysis, and proteomic profiling analysis (studying proteins) on these samples. The goal is to find biomarkers (signs in your body) that can help doctors better understand and potentially diagnose lung cancer earlier. You may be eligible if you are an adult referred to Vanderbilt Medical Center, Veterans Administration Medical Center, St. Thomas Hospital, or Meharry Medical Center for lung cancer evaluation.

Study design: This is an observational study with a planned enrollment of 4000 participants. It is not a treatment study but focuses on collecting and analyzing biological samples.
What's involved: You would provide samples of blood, urine, nasal cells (collected with a brush), sputum, and a small amount of lung tissue (collected during a procedure called fluorescence bronchoscopy).
Compensation: Not stated in the trial record.
Follow-up: The primary endpoint, which is to measure molecular changes, is assessed after the collection of designated samples.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

Molecular Predictors of Cancer in Patients at High Risk of Lung Cancer

Recruiting

Not specifiedAges 18+Observational

Vanderbilt-Ingram Cancer Center

~4,000 participants

Updated 2026-04-27 on ClinicalTrials.gov

What's tested:comparative genomic hybridizationgene expression microarray analysisproteomic profiling analysisbiologic sample preservation procedurenasal brushingBlood draw

At a glance

Recruiting sites

2 of 2 listed sites are recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

To quantitate the molecular changes during lung cancer development

Measured over After collection of designated samples

Conditions

Lung Cancer

Where it's being run

2 sites across 1 states

Tennessee2

Study leadership

Fabien Maldonado, MD · STUDY_CHAIR · Vanderbilt-Ingram Cancer Center

Who to contact

Vanderbilt Ingram Clinical Trials Information Program

1-800-811-8480

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

All adults referred to Vanderbilt Medical Center, Veterans Administration Medical Center, St. Thomas Hospital and Meharry Medical Center for evaluation of signs or symptoms of lung cancer.

Exclusion

Inability to provide informed consent

Minors

Pregnant women

What this trial measures

To quantitate the molecular changes during lung cancer developmentAfter collection of designated samples
As a part of the study nasal brushing specimens, sputum, blood, urine, and a small amount of other tissue will be collected during standard of care procedures (bronchial epithelial, trans-thoracic fine needle aspiration (FNA) and thoracentesis as part of patient work up. Clinical diagnosis is the primary goal of the procedure. All the research specimens are collected after the primary goal of the procedure is met.

Trialytics